NanoKAR

therapeutics

Innovative CAR T cell design

Revolutionized
cancer treatment

One T cell attacking a cancer cell. Cancer cell is bigger and has nodules. T cell is blue.

NanoKAR Therapeutics was founded to revolutionize cancer treatment with a breakthrough, flexible, and scalable CAR-T platform developed and patented by Dr. Bettini at the University of Utah. This next-generation innovation has delivered exceptional preclinical results, demonstrating the potential to not only slow—but completely eradicate—certain cancers.

Learn more

NanoKAR Market, Solutions & Opportunity

• Can be combined with ANY future CAR construct or

• Can be combined with ANY construct that utilizes ITAMs

Current market

$2.78 billion global market, this technology could compete for best in class. North America holds 54% of the market share in revenues

Growth

25.64% anticipated annual growth rate ($34.23 billion by 2034)

Development

Current technology (pre-clinical) improves efficacy, provides tumor specificity, offers a combination therapy, improves persistence and decreases toxicity and dose limitations. Testing to improve efficacy against solid tumors is currently underway.

Opportunities

Scalable- Currently validated with CD19-CD28 and will be tested with CD19-41BB, GD2-CD28, HER2-CD28. Can be combined with ANY future CAR construct that utilized the CD3 zeta chain ITAM or ANY construct that utilized ITAMs

Restricting CD3ζ ITAM diversity while maintaining multiplicity will optimize signaling, effector function and persistence of CAR T cells

Optimal combination of ITAM sequences for
CAR-T function

ITAM sequence optimization of CAR Constructs

27 unique ITAM combinations (AAC, AAB, BCC, BAA etc.)

Can be used as a platform with any CAR construct or with any costimulatory subunit (CD28, 41BB etc.)

or specificity (CD19, GD2, HER2, NECTIN 4 etc.)

or any construct that has an ITAM domain (TCR/BCR/NK receptor etc).

Sustained effector function

Memory formation

Persistence and survival

Environment, target specific responses

Our
Team

Founder
Matt Bettini

Education and Training

Ph.D. 2008 Emory University, Immunology and Molecular Pathogenesis Postdoctoral Research Fellow 2008-2013 St. Jude Children’s Research Hospital

Professional Experience

Assistant Professor 2013-2019, Baylor College of Medicine/Texas Children’s Hospital

Associate Professor 2019-Present, University of Utah